Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies

被引:11
|
作者
Weichseldorfer, Matthew [1 ]
Tagaya, Yutaka [1 ,2 ]
Reitz, Marvin [1 ,2 ]
DeVico, Anthony L. [1 ,2 ]
Latinovic, Olga S. [1 ,3 ]
机构
[1] Univ Maryland, Sch Med, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
关键词
HIV; AIDS pathogenesis; CCR5 coreceptor populations; Conformational changes; PRIMARY-CELLS IMPLICATIONS; CHEMOKINE RECEPTOR CCR5; PROTEIN FLSC IGG1; R5; HIV-1; SYNERGISTIC INHIBITION; MARAVIROC; INDIVIDUALS; MECHANISMS; RESISTANT; SURFACE;
D O I
10.1186/s12967-022-03243-8
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background The chemokine receptor CCR5 is the major coreceptor for HIV-1 cell entry. We previously observed that not all CCR5 mAbs reduce HIV-1 infection, suggesting that only some CCR5 populations are permissive for HIV-1 entry. This study aims to better understand the relevant conformational states of the cellular coreceptor, CCR5, involved in HIV entry. We hypothesized that CCR5 assumes multiple configurations during normal cycling on the plasma membrane, but only particular forms facilitate HIV-1 infection. Methods To this end, we quantified different CCR5 populations using six CCR5 monoclonal antibodies (mAbs) with different epitope specificities and visualized them with super-resolution microscopy. We quantified each surface CCR5 population before and after HIV-1 infection. Results Based on CCR5 conformational changes, down-modulation, and trafficking rates (internalization and recycling kinetics), we were able to distinguish among heterogeneous CCR5 populations and thus which populations might best be targeted to inhibit HIV-1 entry. We assume that a decreased surface presence of a particular CCR5 subpopulation following infection means that it has been internalized due to HIV-1 entry, and that it therefore represents a highly relevant target for future antiviral therapy strategies. Strikingly, this was most true for antibody CTC8, which targets the N-terminal region of CCR5 and blocks viral entry more efficiently than it blocks chemokine binding. Conclusions Defining the virus-host interactions responsible for HIV-1 transmission, including specific coreceptor populations capable of establishing de novo infections, is essential for the development of an HIV-1 vaccine. This study hopefully will facilitate further development of inhibitors to block CCR5 usage by HIV-1, as well as inform future HIV-1 vaccine design.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies
    Matthew Weichseldorfer
    Yutaka Tagaya
    Marvin Reitz
    Anthony L. DeVico
    Olga S. Latinovic
    Journal of Translational Medicine, 20
  • [2] HIV-1 infection and CCR5Δ32 homozygosis
    Ballana, Ester
    Este, Jose A.
    FUTURE VIROLOGY, 2012, 7 (07) : 653 - 658
  • [3] Heterozygous defect in HIV-1 coreceptor CCR5 and chemokine production
    Yang, JY
    Togni, M
    Widmer, U
    CYTOKINE, 1999, 11 (01) : 1 - 7
  • [4] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
    Van Der Ryst, Elna
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [5] Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection
    Yost, Raymond
    Pasquale, Timothy R.
    Sahloff, Eric G.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (08) : 715 - 726
  • [6] Genetic variation within the gene encoding the HIV-1 CCR5 coreceptor in two South African populations
    Picton, Anabela C. P.
    Paximadis, Maria
    Tiemessen, Caroline T.
    INFECTION GENETICS AND EVOLUTION, 2010, 10 (04) : 487 - 494
  • [7] CCR5 inhibitors in HIV-1 therapy
    Dorr, Patrick
    Perros, Manos
    EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) : 1345 - 1361
  • [8] Interaction of small molecule inhibitors of HIV-1 entry with CCR5
    Seibert, Christoph
    Ying, Weiwen
    Gavrilov, Svetlana
    Tsamis, Fotini
    Kuhmann, Shawn E.
    Palani, Anandan
    Tagat, Jayaram R.
    Clader, John W.
    McCombie, Stuart W.
    Baroudy, Bahige M.
    Smith, Steven O.
    Dragic, Tatjana
    Moore, John P.
    Sakmar, Thomas P.
    VIROLOGY, 2006, 349 (01) : 41 - 54
  • [9] Targeting CCR5 trafficking to inhibit HIV-1 infection
    Boncompain, Gaelle
    Herit, Floriane
    Tessier, Sarah
    Lescure, Aurianne
    Del Nery, Elaine
    Gestraud, Pierre
    Staropoli, Isabelle
    Fukata, Yuko
    Fukata, Masaki
    Brelot, Anne
    Niedergang, Florence
    Perez, Franck
    SCIENCE ADVANCES, 2019, 5 (10):
  • [10] Owl monkey CCR5 reveals synergism between CD4 and CCR5 in HIV-1 entry
    Nahabedian, John
    Sharma, Amit
    Kaczmarek, Maryska E.
    Wilkerson, Greg K.
    Sawyer, Sara L.
    Overbaugh, Julie
    VIROLOGY, 2017, 512 : 180 - 186